National Institutes of Health logo
National Institutes of Health

Functional Target Validation for Alzheimer's Disease-Related Dementias

Funds phased research proving a newly identified Alzheimer's-related dementia target truly causes the disease process it's linked to.

Between cyclesNational Institutes of HealthGlobal

A treatment can only be as good as the target it's aimed at, and right now the field has a shortage of well-validated ones. That is the barrier this notice is built to remove for Alzheimer's Disease-Related Dementias (ADRD) and other complex central nervous system disorders — translating a basic discovery into the clinic depends on how rigorously the target was validated, and on real confidence th…

Phased, milestone-gated validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias, developing tools to modulate a candidate target and assess its physiological consequences in vitro and in vivo, then cross-validating the effect across multiple experimental modalities and collaborating laboratories.

CycleiHow often this grant runs - e.g. annually, on a rolling basis, or a one-off call.One-off
Next deadlineiThe next date applications are due. Rolling means you can apply any time.6 Nov 2026
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.-
Award typeiThe form of funding - grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.-
Funding pooliThe total budget available across all awards in this round.$1.8M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Guides for this application

All guides →
Cure Alzheimer's Fund logo
Open

Cure Alzheimer's Fund — Investigator-Initiated

🇺🇸CureAlz · United States

Supports research teams and institutions for Cure Alzheimer's Fund Investigator Initiated in biotechnology, medical technology, and neuroscience.

BiotechMedtech+1
European Commission logo
Scheduled

Cancer Mission: Functional Genomics for New Treatments

🇪🇺European Commission · European Union

Funds €7–8M projects that use functional genomics and patient data to uncover precise new targets for difficult-to-treat cancers.

BiotechMedtech+2
€7M – €8MSep'27
Army Medical Research and Development Command logo
Open

DoW Vision, Translational Research Award

🇺🇸MRDC / CDMRP · United States

Funds translational work turning a vision-research discovery into a drug, device or guideline ready for a definitive clinical trial.

BiotechMedtech
Nov'26
European Commission logo
Scheduled

Clinical trials for advancing innovative interventions for neurodegenerative diseases

🇪🇺European Commission · European Union

Funds early clinical trials of safer, more effective interventions for non-rare neurodegenerative diseases.

MedtechBiotech
€10MApr'27
National Center for Advancing Translational Sciences logo
Open

NCATS Clinical Trial Readiness for Rare Diseases

🇺🇸NCATS · United States

Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.

BiotechMedtech+1
$275KFeb'27
European Commission logo
Scheduled

Innovative healthcare interventions for non-communicable diseases

🇪🇺European Commission · European Union

Funds €7–8M projects that validate innovative interventions for cardiovascular, metabolic, respiratory or kidney disease.

BiotechMedtech
€7M – €8MApr'27